HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mark Berner-Hansen Selected Research

apraglutide

1/2021Comments on "Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome".

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mark Berner-Hansen Research Topics

Disease

2Neoplasms (Cancer)
06/2022 - 05/2022
1Body Weight (Weight, Body)
01/2022
1Short Bowel Syndrome
01/2021
1Anastomotic Leak
01/2020
1Wounds and Injuries (Trauma)
01/2020

Drug/Important Bio-Agent (IBA)

2EicosanoidsIBA
06/2022 - 05/2022
2EnzymesIBA
06/2022 - 05/2022
1Lipoxygenase (Lipoxygenase-1)IBA
05/2022
1Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
05/2022
1Dinoprostone (PGE2)FDA Link
05/2022
1salicylhydroxamic acid (SHAM)IBA
01/2022
1apraglutideIBA
01/2021
1Glucagon (Glukagon)FDA Link
01/2021
1Insulin-Like Growth Factor I (IGF-1)IBA
01/2020
1Glucagon-Like Peptide-2 ReceptorIBA
01/2020
1Messenger RNA (mRNA)IBA
01/2020